BC survivors might experience several underestimated and understudied complications, including post-traumatic stress disorders [5], breast cancer-related lymphedema (BCRL) [6], BC fatigue [7,8], aromatase inhibitor-induced musculoskeletal syndrome [9], cancer treatment-induced bone loss [10], chemo-induced peripheral neuropathy [11], and axillary web syndrome (AWS) [12,13]. The gene discussed is CYP19A1; the disease is breast cancer.